Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes

References

• . Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. 2001;44(8):929–945
   PubMed Web of Science ®Google Scholar
• . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Riddle MC, Kendall DM,. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):34i–43i
   Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J,. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T,. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Calles-Escandon J, Lovato LC, Simons-Morton DG,. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(4):721–727
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Hayden C. Duration of diabetes, HDL levels, and other predictors of CV outcomes. Paper presented at: 69th Scientific Sessions of the American Diabetes Association; June 9, 2009; New Orleans, LA
   Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS,. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( suppl 1):1–68
   PubMedGoogle Scholar
• . International Diabetes Federation (IDF). Guideline for management of postmeal glucose. Brussels, Belgium: International Diabetes Federation (IDF); 2007. http://www.guideline.gov/content.aspx?id=13393. Accessed March 7, 2011
   Google Scholar
• . DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397–405
   PubMedGoogle Scholar
• . Cavalot F, Petrelli A, Traversa M,. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91(3):813–819
   PubMed Web of Science ®Google Scholar
• . Shiraiwa T, Kaneto H, Miyatsuka T,. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun. 2005;336(1):339–345
   PubMed Web of Science ®Google Scholar
• . Santilli F, Formoso G, Sbraccia P,. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost. 2010;8(4):828–837
   PubMed Web of Science ®Google Scholar
• . Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25(10):1845–1850
   PubMed Web of Science ®Google Scholar
• . Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care. 2005;28(11):2626–2632
   PubMed Web of Science ®Google Scholar
• . Temelkova-Kurktschiev TS, Koehler C, Henkel E,. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23(12):1830–1834
   PubMed Web of Science ®Google Scholar
• . Lipour A, Elte JW, van Zaanen HC, Rietveld AP, Cabezas MC. Postprandial inflammation and endothelial dysfuction. Biochem Soc Trans. 2007;35(pt 3):466–469
   PubMed Web of Science ®Google Scholar
• . Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep. 2003;5(6):437–444
   PubMedGoogle Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494
   PubMed Web of Science ®Google Scholar
• . Bibra H, Siegmund T, Ceriello A, Volozhyna M, Schumm-Draeger PM. Optimized postprandial glucose control is associated with improved cardiac/vascular function—comparison of three insulin regimens in well-controlled type 2 diabetes. Horm Metab Res. 2009;41(2):109–115
   PubMed Web of Science ®Google Scholar
• . Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care. 2006;29(1):95–100
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Quagliaro L, Catone B,. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25(8):1439–1443
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Cavarape A, Martinelli L,. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med. 2004;21(2):171–175
   PubMed Web of Science ®Google Scholar
• . Rudofsky G Jr, Reismann P, Schiekofer S,. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res. 2004;36(9):630–638
   PubMed Web of Science ®Google Scholar
• . Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218
   PubMed Web of Science ®Google Scholar
• . Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214–219
   PubMed Web of Science ®Google Scholar
• . Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263–269
   PubMed Web of Science ®Google Scholar
• . Woerle HJ, Neumann C, Zschau S,. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–285
   PubMed Web of Science ®Google Scholar
• . Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care. 2001;24(10):1734–1738
   PubMed Web of Science ®Google Scholar
• . Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther. 2003;5(1):19–26
   PubMedGoogle Scholar
• . Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care. 2003;26(3):791–798
   PubMed Web of Science ®Google Scholar
• . Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31(3 pt 1):233–242
   PubMed Web of Science ®Google Scholar
• . Xu E, Kumar M, Zhang Y,. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab. 2006;3(1):47–58
   PubMed Web of Science ®Google Scholar
• . Hartter E, Svoboda T, Ludvik B,. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34(1):52–54
   PubMed Web of Science ®Google Scholar
• . Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med. 1996;13(9 suppl 6):S19–S24
   Web of Science ®Google Scholar
• . Xiang AH, Peters RK, Kjos SL,. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab. 2004;89(6):2846–2851
   PubMed Web of Science ®Google Scholar
• . Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12( suppl 1):42–46
   PubMedGoogle Scholar
• . Franc S, Dardari D, Peschard C,. Can postprandial blood glucose excursion be predicted in type 2 diabetes? Diabetes Care. 2010;33(9):1913–1918
   PubMed Web of Science ®Google Scholar
• . Canadian Diabetes Association. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2008;32:S1–S201
   Web of Science ®Google Scholar
• . Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008;31( suppl 2):S150–S154
   Web of Science ®Google Scholar
• . Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433–2438
   PubMed Web of Science ®Google Scholar
• . McGill JB, Cole TG, Nowatzke W,; U.S. trial of the GlycoMark assay. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care. 2004;27(8):1859–1865
   PubMed Web of Science ®Google Scholar
• . Christensen BL, Williams M. Assessing postprandial glucose using 1,5-anhydroglucitol: an integrative literature review. J Am Acad Nurse Pract. 2009;21(10):542–548
   PubMed Web of Science ®Google Scholar
• . Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91(3):837–842
   PubMed Web of Science ®Google Scholar
• . Derosa G, Salvadeo SA, D'Angelo A,. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin. 2009;25(3):607–615
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Naditch L; Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001;24(6):989–994
   PubMed Web of Science ®Google Scholar
• . Bao YQ, Zhou J, Zhou M,. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed type 2 diabetes. Clin Exp Pharmacol Physiol. 2010;37(5–6):564–568
   PubMed Web of Science ®Google Scholar
• . Nemoto M, Tajima N, Kawamori R. Efficacy of combined use of miglitol in type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. Acta Diabetol. 2010;48(1):15–20
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB,. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Xu DY, Zhao SP, Huang QX,. Effects of glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;88(1):71–75
   PubMed Web of Science ®Google Scholar
• . O'Keefe JH, Bell DSH. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. J Am Coll Cardiol. 2007;100(5):899–904
   Google Scholar
• . Karl D, Philis-Tsimikas A, Darsow T,. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9(2):191–199
   PubMed Web of Science ®Google Scholar
• . Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009;32(9):1577–1582
   PubMed Web of Science ®Google Scholar
• . Edelman S, Garg S, Frias J,. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189–2195
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Hassman DR, Madder RD,. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27(6):1265–1270
   PubMed Web of Science ®Google Scholar
• . Raskin P, Klaff L, McGill J,; Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. 2003;26(7):2063–2068
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Okerson T, Viswanathan P,. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943–2952
   PubMed Web of Science ®Google Scholar
• . Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010;123( 3 suppl):S28–S37
   PubMed Web of Science ®Google Scholar
• . Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11(4):491–499
   PubMed Web of Science ®Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Nauck M, Bailey T,; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–1456
   PubMed Web of Science ®Google Scholar
• . Abrahamson MJ. Basal insulins: Pharmacological properties and patient perspectives. Prim Care Diabetes. 2010;4( suppl 1):S19–S23
   PubMedGoogle Scholar
• . Horvath K, Jeitler K, Berghold A,. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613
   Google Scholar
• . Ligthelm RJ, Mouritzen U, Lynggaard H,. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114(9):511–519
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31(1):20–25
   PubMed Web of Science ®Google Scholar
• . Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45–52
   PubMed Web of Science ®Google Scholar
• . Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab. 2005;31(1):7–13
   PubMed Web of Science ®Google Scholar
• . Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56–64
   PubMed Web of Science ®Google Scholar
• . Siebenhofer A, Plank J, Berghold A,. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;(2):CD003287
   Google Scholar
• . Anderson JH Jr, Brunelle RL, Keohane P,. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997;157(11):1249–1255
   PubMedGoogle Scholar
• . Ross SA, Zinman B, Campos RV, Strack T; Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med. 2001;24(6):292–298
   PubMed Web of Science ®Google Scholar
• . Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976–1987
   PubMed Web of Science ®Google Scholar
• . Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009;11(1):53–59
   PubMed Web of Science ®Google Scholar
• . Anderson JH Jr, Brunelle RL, Koivisto VA,. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 1997;19(1):62–72
   PubMed Web of Science ®Google Scholar
• . Holman RR, Farmer AJ, Davies MJ,; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–1747
   PubMed Web of Science ®Google Scholar
• . Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22(4):374–381
   PubMed Web of Science ®Google Scholar
• . Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract. 2004;66(1):23–29
   PubMed Web of Science ®Google Scholar
• . Raskin P, Allen E, Hollander P,. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2004:28:260–265
   Web of Science ®Google Scholar
• . Qayyum R, Bolen S, Maruthur N,. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008;149(8):549–559
   PubMed Web of Science ®Google Scholar
• . Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19(5):393–399
   PubMed Web of Science ®Google Scholar
• . Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care. 1999;22(8):1258–1261
   PubMed Web of Science ®Google Scholar
• . McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther. 2002;24(4):530–539
   PubMed Web of Science ®Google Scholar
• . Herz M, Arora V, Campaigne BN,. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J. 2003;93(3):219–223
   PubMed Web of Science ®Google Scholar
• . Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27(8):1113–1125
   PubMed Web of Science ®Google Scholar
• . Velojic-Golubovic M, Mikic D, Pesic M,. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest. 2009;32(1):23–27
   PubMed Web of Science ®Google Scholar
• . Gao Y, Li G, Li Y,. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50. Int J Clin Pract. 2008;62(9):1344–1351
   PubMed Web of Science ®Google Scholar
• . Jang HC, Guler S, Shestakova M; PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008;62(7):1013–1018
   PubMed Web of Science ®Google Scholar
• . Gumprecht J, Benroubi M, Borzi V,; IMPROVE Study Group Expert Panel. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract. 2009;63(6):966–972
   PubMed Web of Science ®Google Scholar
• . Khutsoane D, Sharma SK, Almustafa M,. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212–222
   PubMed Web of Science ®Google Scholar
• . Valensi P, Benroubi M, Borzi V,; IMPROVE Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63(3):522–531
   PubMed Web of Science ®Google Scholar
• . Shah S, Benroubi M, Borzi V,; IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract. 2009;63(4):574–582
   PubMed Web of Science ®Google Scholar
• . Fritsche A, Larbig M, Owens D, Häring HU; GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes—results of the GINGER study. Diabetes Obes Metabol. 2010;12(2):115–123
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Colagiuri S, Gerich J, Tuomilehto J; Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis. 2008;18(4):S17–S33
   Web of Science ®Google Scholar
• . Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag. 2010;6:145–155
   PubMedGoogle Scholar